Incretin Atlas › Trials › Orforglipron CVOT
Orforglipron CVOT
Orforglipron · Atherosclerotic CVD, obesity or T2D
Design
- Molecule(s)
- Orforglipron
- Population
- Atherosclerotic CVD, obesity or T2D
- Official title
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- recruiting · 2025-12 → 2031-08
- Participants
- 7140
- Registry
- NCT07241390
Ongoing outcome trial
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| Orforglipron CVOT | Orforglipron | Atherosclerotic CVD, obesity or T2D ASCVD and/or CKD with obesity or T2D | MACE | 7140 | recruiting | 2031-08 | NCT07241390 |
No results yet; the primary completion date comes from the registry.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Orforglipron CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/orforglipron-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.